BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees

Alghamdi, Ahmed N.; Alotaibi, Mohammed T.; Alqahtani, Adel S. A.; Aboud, Daifullah Al; Abdel‐Moneim, Ahmed S.

doi:10.3389/fmed.2021.760047

Cited by 90 publications

(83 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, those participants were more likely to experience post-vaccination side effects with moderate to severe levels. These findings support the results of a study from Saudi Arabia by Alghamdi et al, which showed that the presence of chronic diseases correlated with the development of post-vaccination side effects [ 84 ]. Moreover, smokers were more susceptible to experience sweating for no reason, whereas non-smokers were more susceptible to experience injection site pain and swelling.…”

Section: Discussionsupporting

confidence: 91%

Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors

et al. 2022

View full text Add to dashboard Cite

Background: The unprecedented global spread of coronavirus disease 2019 (COVID-19) has imposed huge challenges on the healthcare facilities, and impacted every aspect of life. This has led to the development of several vaccines against COVID-19 within one year. This study aimed to assess the attitudes and the side effects among Arab communities after receiving a COVID-19 vaccine and use of machine learning (ML) tools to predict post-vaccination side effects based on predisposing factors. Methods: An online-based multinational survey was carried out via social media platforms from June 14 to 31 August 2021, targeting individuals who received at least one dose of a COVID-19 vaccine from 22 Arab countries. Descriptive statistics, correlation, and chi-square tests were used to analyze the data. Moreover, extensive ML tools were utilized to predict 30 post vaccination adverse effects and their severity based on 15 predisposing factors. The importance of distinct predisposing factors in predicting particular side effects was determined using global feature importance employing gradient boost as AutoML. Results: A total of 10,064 participants from 19 Arab countries were included in this study. Around 56% were female and 59% were aged from 20 to 39 years old. A high rate of vaccine hesitancy (51%) was reported among participants. Almost 88% of the participants were vaccinated with one of three COVID-19 vaccines, including Pfizer-BioNTech (52.8%), AstraZeneca (20.7%), and Sinopharm (14.2%). About 72% of participants experienced post-vaccination side effects. This study reports statistically significant associations (p < 0.01) between various predisposing factors and post-vaccinations side effects. In terms of predicting post-vaccination side effects, gradient boost, random forest, and XGBoost outperformed other ML methods. The most important predisposing factors for predicting certain side effects (i.e., tiredness, fever, headache, injection site pain and swelling, myalgia, and sleepiness and laziness) were revealed to be the number of doses, gender, type of vaccine, age, and hesitancy to receive a COVID-19 vaccine. Conclusions: The reported side effects following COVID-19 vaccination among Arab populations are usually non-life-threatening; flu-like symptoms and injection site pain. Certain predisposing factors have greater weight and importance as input data in predicting post-vaccination side effects. Based on the most significant input data, ML can also be used to predict these side effects; people with certain predicted side effects may require additional medical attention, or possibly hospitalization.

show abstract

Section: Discussionsupporting

confidence: 91%

Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The BNT162b2 (Pfizer-BioNTech) statistics of side effects are contrasting. An ongoing multinational placebo-controlled clinical trial reported 27% ( 34 ), but surveys with self-reported symptoms showed figures between 80 and 92% ( 21 , 22 , 35 ). Ad5-nCoV (CanSinoBIO) and Ad26.CoV2.S (Johnson & Johnson/Janssen) frequencies were close to the ones reported in phase 2 clinical trials.…”

Section: Discussionmentioning

confidence: 99%

“…Both were within the range of self-report surveys. The former has shown prevalence ranging from 51 to 96% ( 21 , 27 , 35 , 38 , 39 ) and the second one, prevalence ranging from 71 to 82% ( 40 , 41 ).…”

Section: Discussionmentioning

confidence: 99%

Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population

Camacho-Moll

Salinas-Martı́nez

Cisneros

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

A few studies examined the comparative side effects of Coronavirus Disease-19 (COVID-19) vaccines. We compared the extension and severity of self-reported side effects of seven COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac Life Sciences), Gam-COVID-Vac (Gamaleya's Sputnik V), Ad5-nCoV (CanSinoBIO), and Ad26.CoV2.S (Johnson & Johnson/Janssen)] in the Mexican population. We also evaluated the association of type of vaccine, sex, age, comorbidity, and history of allergies to the extent and severity of side effects. This was a cross-sectional study carried out online between August 12 and September 3, 2021 in Mexico. The first inclusion criterion was to receive a COVID-19 vaccine and the second, being at least 18 years old. The survey link was distributed via multiple social media platforms. We questioned about the type of vaccine and symptoms based on short-term side effects reported in the literature. Side effect extension was classified as local, systemic, or both. We asked about the need to take medicine, stop activities/miss work, or seek medical attention. Then, a severity index was constructed based on responses. Descriptive and stepwise multivariate logistic ordinal regression analyses were used to calculate odds ratio (OR) and 95% CI for each outcome adjusted by potential confounders. The mean age was 38.9 ± 11.0 years (n = 4,024). Prevalence of at least one side effect varied between vaccines and by a number of doses. At dose 1, ChAdOx1 was the vaccine with the highest rate of at least one side effect (85%) followed by Gam-COVID-Vac (80%). Both were associated to greater extension (adjusted OR 2.53, 95% CI 2.16, 2.96 and adjusted OR 2.41, 95% CI 1.76, 3.29, respectively) and severity of side effects (adjusted OR 4.32, 95% CI 3.73, 5.00 and adjusted OR 3.00, 95% CI 2.28, 3.94, respectively). Young age (<50 years), female sex, comorbidity, and history of allergies were associated with greater extension and severity, independent of the type of vaccine and potential confounders. At dose 2, mRNA-1273 was the vaccine with the highest rate of side effects (88%) and the only vaccine associated to greater extension (adjusted OR 2.88, 95% CI 1.59, 5.21) and severity of symptoms (adjusted OR 3.14, 95% CI 1.82, 5.43). Continuous studies are necessary to acknowledge more post-vaccine symptoms in different populations.

show abstract

“…Some patients might already have an underlying illness that can cause thrombosis regardless of COVID-19 or COVID-19 vaccination [ 24 ]. Some recent Arabic reports showed that the incidence of thrombocytopenia and peculiar thrombotic events might be more common in viral vector technology based COVID-19 vaccine [ 25 , 26 ]. According to the recent management recommendation, mass COVID-19 vaccination should continue but with special caution [ 27 ].…”

Section: Pathophysiology Of Thrombotic Disorder and Problem In Covid-19/covid-19 Vaccinationmentioning

confidence: 99%

COVID-19, neurovascular thrombotic problem and short summary on blood coagulation disorder: a brief review

Mungmunpuntipantip¹,

Wiwanitkit

2022

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

COVID-19 is the present global public health problem. This respiratory viral infection can manifest atypical presentation including neurological presentations. An important neurological problem in COVID-19 is neurovascular thrombosis. The basic pathogenesis of thrombosis in neurological system is explainable by the basic principle of thrombohemostasis. A hypercoagulability is a possible problem seen in some COVID-19 cases. In this brief review, the authors summarize venous and arterial thrombosis of neurovascular system as a complication of COVID-19. The updated pathophysiology of COVID-associated blood coagulation disorder is discussed. In addition, consideration regarding new COVID-19 vaccine related thrombotic adverse event is also raised.

show abstract

BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees

Cited by 90 publications

References 37 publications

Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors

Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors

Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population

COVID-19, neurovascular thrombotic problem and short summary on blood coagulation disorder: a brief review

Contact Info

Product

Resources

About